Aspire Submits Registration Statement for US IPO

Feb.22.2023
Aspire Submits Registration Statement for US IPO
Aspire, an e-cigarette and CBD product company, submitted registration to list on NASDAQ with an expected $155.25 million in funding.

On February 20th, the electronic cigarette and CBD product company, Aspire, filed a registration statement to go public on the US stock market.


The company intends to go public on the NASDAQ stock exchange, with a proposed maximum share price of $9 and the aim of raising $155.25 million by issuing 17.25 million shares. The registration statement provides details on the company's current operations, risk factors, and equity structure.


The parent company of Aspire, a business department, is a manufacturer of vape and CBD products. The total global retail sales of vape products from 2015 to 2020 and the retail sales forecast for 2021 to 2024 are also presented in the registration document (see chart below).


Source: US Securities and Exchange Commission


According to data, during the early days of the company's establishment (2015-17), an open system was more welcomed by the market. However, since the gradual replacement of open vaping systems with closed ones, closed systems have become the mainstream in the market and surpassed open systems in 2019. That year, the global sales of closed vaping systems reached $9.688 billion, surpassing open systems' $8.392 billion.


The company predicts that closed systems will continue to dominate the market and that global vape sales will reach $66.8 billion by 2023.


Since 2019, the company has been expanding its CBD market in the United States and Canada. In 2020, the global sales of cannabis products reached $2.9 billion.


Source: U.S. Securities and Exchange Commission


In addition, the company also undertakes OEM/ODM business for electronic atomization systems.


According to Aspire's registration document, the company's main market is Europe, with the European market accounting for 61% of the company's total performance in 2020, followed by 22.6% in the United States. Their efforts to expand in the Asia-Pacific market have been significant, increasing from 0.1% in 2019 to 9.5%.


Source: U.S. Securities and Exchange Commission.


The risk factors listed in the registration statement of the company are as follows:


Existing and newly enacted laws, regulations, and policies could present barriers to the company's future business operations and have significant adverse effects. Currently, the company can only legally sell one product, Nautilus Prime, in the US, which accounted for less than 11% of the company's US revenues in the year ending June 30, 2020. As a result, the company can no longer sell products that accounted for more than 89% of their US revenues in that same period, leading to a decline in US sales in the six months ending December 31, 2020. The market for cannabis vaporization products is still immature, with most sales occurring in the US, and expansion in the US or globally is not guaranteed. Recently, joint statements from the US Securities and Exchange Commission and the Public Company Accounting Oversight Board, proposed rule changes from NASDAQ, and a bill passed by the US Senate have all called for stricter standards when evaluating the qualifications of auditors for emerging market companies, especially those auditors that are not subject to PCAOB inspections outside of the US. These developments could increase uncertainty around the company's issuances. If there is evidence to suggest or research to show that the use of electronic vaporization or cannabis products poses long-term health risks, the use of such products could significantly decrease, which would have a substantial adverse impact on the company's business, financial condition, and operating performance. The company's operations entail inherent risks and uncertainties, including developments in regulatory environments, medical discoveries, and the market's acceptance of electronic cigarette devices. The company faces potential adverse effects due to sales, product liability, and user complaints. Misuse or abuse of the company's products could lead to potential adverse health effects, leading to complaints, product liability claims, and negative publicity. The company faces competition in the electronic vaporization industry, including larger, more well-known companies with a significantly larger market share, and Aspire may not effectively compete. In addition, widespread outbreaks of diseases, natural disasters, or improper behavior by employees or distributors could harm the company's interests and reputation and have an adverse impact on its business operations.


2FIRSTS will continue to follow this topic and provide timely updates. Stay tuned for our latest coverage.


Reference:


Aspire has filed a registration statement with the U.S. Securities and Exchange Commission.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special report|Indonesia's Vape Industry Has 200 Manufacturers and $1.7 Billion in Investment. Could a Regulatory Divide Derail Its Rise as the World's No. 2 Manufacturing Hub After Shenzhen?
Special report|Indonesia's Vape Industry Has 200 Manufacturers and $1.7 Billion in Investment. Could a Regulatory Divide Derail Its Rise as the World's No. 2 Manufacturing Hub After Shenzhen?
Indonesia's Ministry of Industry said at a November 3, 2026, policy forum that the country has about 200 electronic cigarette companies, Rp31 trillion (approximately $1.71 billion) in cumulative industry investment and around 100,000 jobs across the supply chain. The National Narcotics Agency is seeking a comprehensive ban on vape use and circulation, while the industry ministry favors tighter import, product-standard and distribution controls. Indonesia exported approximately $518 million in vaping products in 2025, and Chinese manufacturers including Smoore, GEEKVAPE and Jinjia Group have established local operations. An international logistics specialist interviewed by 2Firsts said more Chinese vape companies began production in Indonesia from the second half of 2025, accompanied by increased shipments of manufacturing equipment and investment in logistics facilities. The regulatory debate comes as Indonesia expands its role in international vaping manufacturing.
Special Report
Nov.05
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
During its coverage of Altria's booth at NACS Show 2026, 2Firsts documented product displays that prompted questions about U.S. tobacco advertising warning requirements. Following public comments from a former FDA official, 2Firsts sought responses from Altria and independently consulted U.S. regulatory lawyer Azim Chowdhury. Altria maintained that its B2B communications complied with applicable laws, while Chowdhury explained that federal warning rules provide no general trade-show exemption for e-cigarettes and nicotine pouches. The special report examines the broader regulatory implications.
Nov.04
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
The UK's Vaping Products Duty will take effect on October 1, 2026, at a flat rate of £2.20 per 10ml of vaping liquid. Ahead of implementation, DOJO, PIXL and Hayati have introduced or been reported to be adding lower-capacity tiers alongside larger products. DOJO has added a 6ml BLAST7K Fresh below its 10ml BLAST10K Fresh, PIXL offers both a 12ml 8000 and a 6ml 5K, while retailer Ninja Vapes says Hayati is preparing a 7ml 4K alongside its existing 12ml 6K. The pattern points to a growing lower-capacity tier in the UK market, although the brands have not all explicitly linked the changes to the new duty.
Sep.23
Russia's Vape Ban Decisions Reach 17 Regions With 39 More Considering Laws, Putting Over 3,000 St. Petersburg Retail Outlets in Focus
Russia's Vape Ban Decisions Reach 17 Regions With 39 More Considering Laws, Putting Over 3,000 St. Petersburg Retail Outlets in Focus
Russia's regional vape retail restrictions are expanding. State Duma Speaker Vyacheslav Volodin said on November 7 that 17 regions had adopted decisions to ban vape sales, while another 39 were preparing or considering similar legislation. On November 12, lawmakers in Leningrad Oblast and the Republic of Karelia adopted bans scheduled to begin on March 1, 2027. A day earlier, St. Petersburg unanimously approved a five-year ban proposal in its first reading. The city has 615 specialist vape shops and more than 2,400 other retail outlets selling vaping products alongside other goods. Under Federal Law No. 186-FZ, enacted in June 2026, Russian regions may prohibit retail sales of electronic nicotine delivery systems and related liquids between March 2027 and March 2032. The legislation also restricts licensed suppliers from delivering covered products to retail premises in regions where bans apply.
Regulations
Nov.13
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Japan Tobacco International (JTI) has introduced PERLZ nicotine pearls in the UK, expanding its oral nicotine portfolio beyond conventional nicotine pouches. The fully dissolvable, multi-layer pearls are placed under the tongue and come in Mint and Berry flavors at concentrations of 1mg/g and 2mg/g, equivalent to approximately 0.3mg and 0.5mg of nicotine per pearl. UK retailer Haypp published four 30-pearl dispenser listings on July 31, 2026, followed by three 10-pearl sachet products on August 17. The dispensers retail for £6.50, while the sachets cost £2.50.
product
Oct.12